Beijing Tiantan Biological Products Corp Ltd
SSE:600161
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.5
32.16
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Corp Ltd
Revenue
Beijing Tiantan Biological Products Corp Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
|
Revenue
¥5.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥17.4B
|
CAGR 3-Years
102%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Revenue
¥8.3B
|
CAGR 3-Years
37%
|
CAGR 5-Years
31%
|
CAGR 10-Years
27%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
¥46.7B
|
CAGR 3-Years
30%
|
CAGR 5-Years
42%
|
CAGR 10-Years
51%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Revenue
¥2.9B
|
CAGR 3-Years
59%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
Beijing Tiantan Biological Products Corp Ltd
Glance View
Beijing Tiantan Biological Products Corp. Ltd. engages in the research and development, production and sale of biological products. The company is headquartered in Beijing, Beijing and currently employs 3,933 full-time employees. The Company’s primary products include preventive products, blood products and other biological products, such as the influenza A (H1N1) vaccines (split, inactivated),hepatitis B vaccines, poliomyelitis vaccines, measles-mump-rubella (MMR) vaccines, encephalitis B vaccines, influenza vaccinations, bacterial vaccines, human serum albumin (HSA) and intravenous immunoglobulin (IVIG), among others. The firm mainly distributes its products within domestic markets and to Hong Kong markets.
See Also
What is Beijing Tiantan Biological Products Corp Ltd's Revenue?
Revenue
5.3B
CNY
Based on the financial report for Jun 30, 2024, Beijing Tiantan Biological Products Corp Ltd's Revenue amounts to 5.3B CNY.
What is Beijing Tiantan Biological Products Corp Ltd's Revenue growth rate?
Revenue CAGR 10Y
10%
Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Beijing Tiantan Biological Products Corp Ltd have been 13% over the past three years , 10% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
